Clinical symptoms, diagnosis, and treatment of neurocysticercosis

被引:343
|
作者
Garcia, Hector H. [1 ,2 ,3 ]
Nash, Theodore E. [4 ]
Del Brutto, Oscar H. [5 ,6 ]
机构
[1] Inst Ciencias Neurol, Cysticercosis Unit, Lima 1, Peru
[2] Univ Peruana Cayetano Heredia, Ctr Global Hlth Tumbes, Lima, Peru
[3] Univ Peruana Cayetano Heredia, Sch Sci, Dept Microbiol, Lima, Peru
[4] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
[5] Univ Espiritu Santo Ecuador, Sch Med, Guayaquil, Ecuador
[6] Hosp Clin Kennedy, Dept Neurol Sci, Guayaquil, Ecuador
来源
LANCET NEUROLOGY | 2014年 / 13卷 / 12期
基金
英国惠康基金; 美国国家卫生研究院;
关键词
SOLITARY CYSTICERCUS GRANULOMA; TAENIA-SOLIUM TAENIASIS; CENTRAL-NERVOUS-SYSTEM; CALCIFIED NEUROCYSTICERCOSIS; FOLLOW-UP; CEREBRAL CYSTICERCOSIS; SEIZURE RECURRENCE; HYDROCEPHALUS SECONDARY; COGNITIVE IMPAIRMENT; PRAZIQUANTEL THERAPY;
D O I
10.1016/S1474-4422(14)70094-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The infection of the nervous system by the cystic larvae of Taenia solium (neurocysticercosis) is a frequent cause of seizure disorders. Neurocysticercosis is endemic or presumed to be endemic in many low-income countries. The lifecycle of the worm and the clinical manifestations of neurocysticercosis are well established, and CT and MRI have substantially improved knowledge of the disease course. Improvements in immunodiagnosis have further advanced comprehension of the pathophysiology of this disease. This knowledge has led to individualised treatment approaches that account for the involvement of parenchymal or extraparenchymal spaces, the number and form of parasites, and the extent of degeneration and associated inflammation. Clinical investigations are focused on development of effective treatments and reduction of side-effects induced by treatment, such as seizures, hydrocephalus, infarcts, and neuroinjury.
引用
收藏
页码:1202 / 1215
页数:14
相关论文
共 50 条
  • [21] NEUROCYSTICERCOSIS - PARASITOLOGY, CLINICAL PRESENTATION, DIAGNOSIS, AND RECENT ADVANCES IN MANAGEMENT
    COOK, GC
    QUARTERLY JOURNAL OF MEDICINE, 1988, 68 (256): : 575 - 583
  • [22] Evaluation of an enzyme immunoassay for clinical diagnosis of neurocysticercosis in symptomatic patients
    de Carvalho Junior, Reynaldo Mendes
    Costa, Dorcas Lamounier
    Soares, Savyo Carvalho
    Nery Costa, Carlos Henrique
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2010, 43 (06) : 647 - 650
  • [23] Inflammation in neurocysticercosis: clinical relevance and impact on treatment decisions
    Hamamoto Filho, Pedro T.
    Fragoso, Gladis
    Sciutto, Edda
    Fleury, Agnes
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (12) : 1503 - 1518
  • [24] Mood and psychotic symptoms with neurocysticercosis
    Bourgeois, JA
    Motosue, J
    Mehra, N
    PSYCHOSOMATICS, 2002, 43 (04) : 337 - 338
  • [25] DIAGNOSIS AND MANAGEMENT OF NEUROCYSTICERCOSIS
    AGGARWAL, SK
    HOSPITAL PRACTICE, 1993, 28 (04): : 106 - &
  • [26] Diagnosis of subarachnoid neurocysticercosis
    Channel, Ivan Christian
    Damara, Fachreza Aryo
    Ramdhani, Alfya Nandika
    Anton, Anton
    NEUROSURGICAL FOCUS, 2021, 50 (05)
  • [27] ELISA IN THE DIAGNOSIS OF NEUROCYSTICERCOSIS
    ROSAS, N
    SOTELO, J
    NIETO, D
    ARCHIVES OF NEUROLOGY, 1986, 43 (04) : 353 - 356
  • [28] SIGNIFICANCE OF CLINICAL SYMPTOMS FOR DIAGNOSIS AND TREATMENT OF CORONARY HEART-DISEASE
    HOFLING, B
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1984, 126 (22): : 719 - 721
  • [29] Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment
    Santini, D.
    Armento, G.
    Giusti, R.
    Ferrara, M.
    Moro, C.
    Fulfaro, F.
    Bossi, P.
    Arena, F.
    Ripamonti, C., I
    ESMO OPEN, 2020, 5 (06)
  • [30] DATURA-STRAMONIUM POISONING - DIAGNOSIS AND TREATMENT ARE BASED ON CLINICAL SYMPTOMS
    ROBLOT, F
    MONTAZ, L
    DELCOUSTAL, M
    GABORIAU, E
    CHAVAGNAT, JJ
    MORICHAUD, G
    POURRAT, O
    SCEPI, M
    PATTE, D
    REVUE DE MEDECINE INTERNE, 1995, 16 (03): : 187 - 190